ClinicalTrials.gg
Not yet recruitingNCT07450053Updated Mar 4, 2026

A Study (Phase 1b/2) of GenSci134 in Children With Idiopathic Short Stature (ISS)

A Phase 1/2 interventional study of GenSci134 Injection and Recombinant Human Growth Hormone Injection(Norditropin® FlexPro®) in Idiopathic Short Stature, sponsored by Changchun GeneScience Pharmaceutical Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 3 Years to 12 Years. Per ClinicalTrials.gov, last updated 2026-03-04.

Sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
128
Allocation
Randomized
Ages
3 Years to 12 Years
Sex
All
01

Study summary

This study comprises two phases: Phase Ib and Phase II. Phase Ib is a multicenter, randomized, open-label, active-controlled, single-dose, dose-escalation study to evaluate the safety, tolerability, PK/PD profile, and immunogenicity of a single subcutaneous dose of GenSci134 in children with idiopathic short stature (ISS).

Phase II is a multicenter, randomized, open-label, active-controlled, multiple-dose, parallel-group study to assess the efficacy and safety of multiple subcutaneous doses of GenSci134 at different levels versus Norditropin® in children with ISS. It will also evaluate PK/PD profile, immunogenicity, and biomarkers to support dose selection for Phase III.

02

Conditions studied

  • Idiopathic Short Stature

Keywords

  • ISS
  • GenSci134
03

In context

Lead sponsor

Changchun GeneScience Pharmaceutical Co., Ltd. is the lead sponsor of 112 studies on the registry; 48 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • sInformed consent of parent or legal representative of participant and child assent, as age appropriate must be obtained before any study-related activities.
  • At the time of signing the form (ICF), the following conditions must be met:
  • Phase Ib:

Girls: age ≥3 and ≤11 years, breast development at Tanner stage 1, body weight ≥16 kg; Boys: age ≥3 and ≤12 years, testis volume \<4 mL, body weight ≥16 kg.

● Phase II: Girls: age ≥3 and ≤9 years, breast development at Tanner stage 1; Boys: age ≥3 and ≤10 years, testis volume \<4 mL.

  • Diagnosis of ISS at the time of ICF signing .
  • within the range of ±2 SD of the mean BMI for age and sex at screening(Phase II only).
  • No prior exposure to GH or IGF-1 therapy.
  • Historical measurements of body height within 6-18 months prior to screening are available(Phase II only).
  • BA-CA ≤ 1 year at screening(Phase II only).

Exclusion criteria

Exclusion Criteria:

  • Presence of any suspected or confirmed condition known to affect growth, including but not limited to:

    1. GHD.
    2. Turner Syndrome.
    3. Noonan syndrome.
    4. Laron Syndrome.
    5. Other genetic syndromes with short stature that are caused by chromosomal abnormalities or gene mutations, including but not limited to Prader-Willi syndrome, abnormal SHOX-1 gene analysis, or GH receptor deficiency.
    6. Born small for gestational age:
    7. Growth retardation due to malnutrition.
    8. Growth retardation due to hypothyroidism.
    9. Short stature with any other clearly identified etiology.
  • Epiphyseal closure (Phase II only).
  • Abnormal liver function, renal function, or coagulation profile.
  • Current or prior history of any malignant disease; or a family history of .
  • Presence of impaired glucose metabolism, or ≥ 5.7%, or a confirmed diagnosis of diabetes mellitus.
  • Clear medical history of cardiovascular, hepatic, renal, gastrointestinal, respiratory, hematological, neurological, or metabolic disorders, or any other condition that, in the opinion of the investigator, makes the participant unsuitable for participation in the study.
  • Any abnormality in vital signs, physical examinations, laboratory tests, 12-lead , full spine anteroposterior and lateral X-ray, or B-mode ultrasound, other than those associated with the study disease, as judged by the investigator and will make the participant unsuitable for the study.
  • A positive result for any of the following serological tests during the screening period: , Anti-, Anti-, or TP-Ab.
  • Known highly allergic diathesis or to growth hormone products or any of the drug.
  • Use within a specified period prior to screening or planned use during the study of medications that may interfere with growth hormone secretion or action, or other drugs known to affect growth and development.
  • Participation in another clinical trial within 3 months prior to screening, or if the time since the last dose is less than 5 half-lives of the previous investigational drug at screening.
  • Children have been treated with systemic treatment for longer than 2 consecutive weeks within the last 3 months prior to screening (Phase II only).
  • Children have been treated with inhaled budesonide or equivalent doses of inhaled glucocorticoids for more than 4 consecutive weeks within the last 12 months prior to screening (Phase II only).
  • Receipt of any blood products within 3 months prior to the first dose, poor peripheral venous access, or any medical condition that will preclude tolerance of the blood sampling procedures.
  • Administration of any vaccine within 14 days prior to the first dose or planned vaccination at any time during the study period.
  • The participant and/or the parent/legal representative is likely to be non-compliant with respect to study conduct, as judged by the investigator.
  • Any other condition that, in the opinion of the investigator, makes the participant unsuitable for participation in the study.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
128 participants (estimated)

Study arms

  • Experimental
    Dose Level 1~ Dose Level 6

    dose level 1、dose level 2、dose level 3、dose level 4、 dose level 5、dose level 6

    Drug: GenSci134 Injection

  • Active comparator
    Recombinant Human Growth Hormone Injection (Norditropin®)

    Active control group

    Drug: Recombinant Human Growth Hormone Injection(Norditropin® FlexPro®)

Interventions

06

What researchers measure

Primary outcomes

  1. Phase Ib: Incidence of Treatment Emergent Adverse Events (TEAEs)

    Time frame: From Day 1 to Day 35

  2. Phase II: Annualized height velocity (AHV) at Week 24 of treatment

    Time frame: 24 weeks

Secondary outcomes

  1. Phase Ib: Areas under the drug concentration-time curve (AUC0-t, AUC0-∞) of GenSci134

    Time frame: From Day 1 to Day 29

  2. Phase Ib: Time to maximum concentration (Tmax) of GenSci134

    Time frame: From Day 1 to Day 29

  3. Phase Ib: Maximum concentration (Cmax) of GenSci134

    Time frame: From Day 1 to Day 29

  4. Phase Ib: Half-life (t1/2) of GenSci134

    Time frame: From Day 1 to Day 29

  5. Phase Ib: Serum level of IGF-1and IGFBP-3 and their changes from baseline.

    Time frame: rom Day 1 to Day 29

  6. Phase Ib: Incidence and timing of positive anti-drug antibody (ADA) and/or neutralizing antibody (NAb) (if applicable)

    Time frame: From Day 1 to Day 29

  7. Phase II: Change from baseline in HT SDS at each visit

    Time frame: From baseline to Week 24 of the treatment period

  8. Phase II: Change from baseline in AHV at each visit

    Time frame: From baseline to Week 24 of the treatment period

  9. Phase II: Change from baseline in BA/CA at each visit

    Time frame: From baseline to Week 24 of the treatment period

  10. Phase II: Incidence of TEAEs

    Time frame: From the first dose to the end of the trial

  11. Phase II: Serum concentration of GenSci134.

    Time frame: From baseline to Week 24 of the treatment period

  12. Phase II: Serum level of IGF-1and IGFBP-3 and their changes from baseline.

    Time frame: From baseline to Week 24 of the treatment period

  13. Phase II: Incidence and timing of positive ADA and/or NAb (if applicable).

    Time frame: From baseline to Week 24 of the extension period

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2026; primary completion for Jul 2028, 28 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2026
First posted
Mar 4, 2026
StartEst.
Mar 6, 2026
Primary completionEst.
Jul 18, 2028
CompletionEst.
Dec 31, 2028
Last update
Mar 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07450053
Responsible party
Sponsor
First posted
Mar 4, 2026
Start date
Mar 6, 2026 (estimated)
Primary completion
Jul 18, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Mar 4, 2026

Study contacts

Jinbo Li
Contact
lijinbo@genscigroup.com
+86 15001322766

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GENSCI134

Start the discussion